近日，江苏吴中医药发展股份有限公司（简称"江苏吴中""*ST苏吴"）接连披露4条公告，涉及公司股票 停牌暨将被终止上市的风险提示公告，中国证监会下发的《行政处罚决定书》等。因未如实披露实际控 制人，以及虚增营业收入、营业成本和利润等，江苏吴中触及重大违法强制退市情形，其公司股票已于 2025年11月26日停牌。从历经多次跨界转型失败，到闯入医美赛道实现业绩翻身，江苏吴中何以走到退 市边缘？ 合计罚款3050万元、实控人"禁业"10年 中国证监会最新下发的《行政处罚决定书》，揭开了江苏吴中长达数年的违法"遮羞布"。 经查明，江苏吴中及相关人员未如实披露实际控制人，2018年至2023年年度报告存在虚假记载；虚增营 业收入、营业成本和利润，2020年至2023年年度报告存在虚假记载。 2018年2月，江苏吴中控股股东苏州吴中投资控股有限公司发生股权变更，变更后，钱群山实际支配江 苏吴中行为，成为江苏吴中实际控制人。江苏吴中2018年至2023年年度报告披露钱群英为实际控制人， 存在虚假记载。 江苏吴中子公司江苏吴中进出口有限公司、中吴贸易发展（杭州）有限公司、江苏吴中海利国际贸易有 限公司通过与浙江优诺德贸易有限 ...

Core Viewpoint - *ST Suwu, after 26 years of listing, is facing forced delisting due to four consecutive years of financial fraud and significant fund misappropriation, potentially becoming the ninth major illegal delisting company by 2025 [1][3][17] Financial Fraud - From 2020 to 2023, *ST Suwu engaged in continuous financial fraud, with inflated profits peaking at 51.65%. The total inflated profit amounted to 0.76 billion, with inflated operating income and costs reaching 1.772 billion and 1.695 billion respectively [6][17] - The proportion of inflated profits was notably high, with over 25% of profits being fraudulent from 2021 to 2023, and the highest in 2021 at 51.65% [6][17] Fund Misappropriation - *ST Suwu has experienced severe fund misappropriation, with the highest misappropriation rate reaching 96.09%. The non-operating fund misappropriation from 2020 to 2023 was recorded at 1.27 billion, 1.393 billion, 1.543 billion, and 1.693 billion respectively, representing 6.88%, 74.20%, 84.60%, and 96.09% of the net assets [7][8][17] - As of 2024, there remains 769 million in misappropriated funds that have not been returned [8] Disclosure Issues - The actual controller of *ST Suwu changed in February 2018, but this was not disclosed in annual reports from 2018 to 2023 [10][11] - The company has faced multiple penalties and has been under investigation by the China Securities Regulatory Commission (CSRC) for information disclosure violations [3][13] Regulatory Environment - The new delisting regulations effective from January 1, 2025, have tightened the criteria for major illegal delisting, particularly focusing on financial fraud [17][18] - Since the tightening of regulations, eight companies have already faced delisting due to financial fraud, with *ST Suwu likely to follow [1][18] Investor Protection - In response to the crackdown on financial fraud, investor protection measures are being enhanced, including civil compensation lawsuits initiated by investors against *ST Suwu [19]

Core Viewpoint - *ST Suwu (600200) is facing mandatory delisting due to four consecutive years of financial fraud and significant fund misappropriation, potentially becoming the ninth major company to be delisted for serious violations by 2025 [1][2][3] Financial Fraud - From 2020 to 2023, *ST Suwu engaged in continuous financial fraud, with profit inflation peaking at 51.65% in 2021. The total inflated profit amounted to 0.76 billion yuan, with inflated operating income and costs reaching 1.772 billion yuan and 1.695 billion yuan respectively [6][7] - The proportion of inflated profits was notably high, with over 25% of profits being fraudulent from 2021 to 2023, and 2021 seeing the highest inflation rate at 51.65% [6] Fund Misappropriation - *ST Suwu has experienced severe fund misappropriation, with the highest rate reaching 96.09% of its net assets by 2023. The non-operational fund occupation by related parties increased significantly from 1.27 billion yuan in 2020 to 16.93 billion yuan in 2023 [7][8] - By 2023, over 70% of *ST Suwu's net assets had been "emptied," with 7.69 billion yuan of misappropriated funds still outstanding [8] Disclosure Issues - The company failed to disclose a change in its actual controller for six years, which occurred in February 2018, leading to significant penalties [9] - The company and its main responsible individuals were fined a total of 30.5 million yuan, with the chairman facing the highest penalty of 15 million yuan and a 10-year market ban [9] Regulatory Environment - The new delisting regulations effective from January 1, 2025, have tightened the standards for mandatory delisting, particularly focusing on financial fraud [2][14] - Since the tightening of regulations, eight companies have already faced delisting procedures due to serious violations, indicating a trend towards stricter enforcement [14] Company Background - *ST Suwu, established in 1994 and listed in 1999, has struggled with poor performance in its core pharmaceutical and real estate businesses, leading to continuous losses from 2018 to 2023 [11] - Despite a brief recovery in 2024 due to a new product line, the company reported a net loss of 0.74 billion yuan in the first quarter of 2025 [11] Legal and Investor Protection - Following the investigation into *ST Suwu, investors have begun filing civil compensation lawsuits, supported by new measures for investor protection [15] - The introduction of advance compensation and commitments from administrative enforcement parties aims to enhance investor rights and recovery options [15]